Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens

Yair Herishanu, Mudi Misgav, Ilya Kirgner, Ofira Ben-Tal, Amiram Eldor, Ella Naparstek

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment with intensive chemotherapy regimens is frequently complicated by severe thrombocytopenia. During the period of severe thrombocytopenia, anticoagulant treatment is not uncommonly indicated for thromboembolic events or thromboprophylaxis in these patients. We report 10 hematological patients treated with intensive chemotherapy protocols that were anticoagulated with enoxaparin for catheter related central venous thrombosis and thromboprophylaxis. During the period of severe thrombocytopenia the dosages of enoxaparin were reduced and no major bleeding occurred. Based on our experience we suggest that reduced dosages of low molecular weight heparins may be used relatively safely during transient severe thrombocytopenia.

Original languageEnglish
Pages (from-to)1407-1411
Number of pages5
JournalLeukemia and Lymphoma
Volume45
Issue number7
DOIs
StatePublished - Jul 2004

Keywords

  • Catheter related central vein thrombosis
  • Enoxaparin
  • Intensive chemotherapy regimen
  • Low molecular weight heparin
  • Thrombocytopenia

Fingerprint

Dive into the research topics of 'Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens'. Together they form a unique fingerprint.

Cite this